The downgrade reflects skepticism regarding the upcoming Phase 3 trial results for Opakalim. Analysts warned that even in an optimistic scenario, the data likely will appear undifferentiated compared to azetukalnar, an investigative treatment currently in development by Xenon Pharmaceuticals. This lack of clear clinical advantage threatens the consensus projection that Opakalim could generate $1 billion in peak annual sales.
In section Market Quotes
Biohaven Shares Slip as Bank of America Questions Epilepsy Drug Potential
Bank of America analysts downgraded Biohaven to underperform on Monday, citing concerns that the company’s experimental epilepsy drug, Opakalim, will struggle to compete with rival treatments. The shift in outlook triggered a 6.3% decline in shares, pushing the stock price down to $14.84 during afternoon trading.
Beyond the competitive landscape, the firm cited broader financial risks, noting that Biohaven faces a tightening cash runway. With the company's only other major 2026 catalyst—a drug candidate in the obesity space—carrying limited derisking value, analysts opted to cut their price target from $12 to $11. Despite Monday’s retreat, the stock retains a 31% gain for the year.
Comments (0)
No comments yet. Be the first!